PDCD1 and non-small cell lung carcinoma: In addition, the treatment of NSCLC and upper gastrointestinal tract cancer with D monotherapy or in combination with anti-PD-1/PD-L1 is currently being evaluated in four phase III clinical trials, including ARC-10 (NCT04736173), PACIFIC-8 (NCT05211895) [191], STAR-121 (NCT05502237), and STAR-221 (NCT05568095).